Abstract: Described herein are integrated programs and systems that manage or treat chronic conditions such as elevated cholesterol or elevated blood pressure and other health conditions. The integrated system may include a combination of: a dietary supplement; behavior change messaging through packaging (including use of unit dose packaging) and/or package inserts; video content available through the web or mobile means; interactive discussions with healthcare providers; and an app or website that supports behavior change as well as tracks ongoing compliance to the dietary supplement and behavior change as well as physiologic endpoints. The integrated system may thus create a routine set of behaviors for the user to help manage or treat various health conditions.

Abstract: Improved passive resistance nasal devices for treating a patient (and particularly, but not exclusively, a sleeping patient) that inhibit exhalation more than inhalation. For example, described herein are passive-resistance nasal devices having a variable sized opening leak path that change the size of the leak path opening depending on the pressure extended across the nasal device. Also described herein are passive nasal devices including a deployable insertion guide member. Also described herein are passive nasal devices including an extension member to hold the airflow resistor portion of the nasal device slightly apart from the subject's nose, even as the nasal device itself may be secured against the nose or nostril openings. Methods of operating these nasal devices and methods of treating patients using these devices are also described.

Abstract: Described herein are nasal devices, including nasal devices formed in layers having four or fewer layers. In some variations, the nasal devices include a single integrated layer from which the flap of the airflow resistor is formed as well as the base of the holdfast region. The nasal devices may include a single aligner or rim body on the side of the device facing the subject. The aligner may protect the airflow resistor, and may help center or position the nasal device. In some variations, these nasal devices may include a noise-reduction feature. Also described herein are systems, devices and methods for determining if a passive nasal respiratory device having an airflow resistor configured to inhibit exhalation more than inhalation has been worn by a subject, and thereby confirming compliance.

Abstract: Described herein are combined active PAP/passive EPAP interface devices to transmit positive air pressure from a PAP source to the user, but provide passive EPAP when the PAP source is disabled. These interface device may continue to provide benefit to the user even if the PAP source becomes disconnected or otherwise fails. The interface devices described herein include a passive EPAP airflow resistor configured to provide expiratory positive airway pressure (“EPAP”). These interface devices may also include quick connects and/or disconnects for releasably connecting to the source of pressurized breathable gas, a quick release for disconnecting from the source of pressurized breathable gas, and an adhesive user interface region that connects the device the user's face. Also described are adapter for converting a PAP interface devices into combined active PAP/passive EPAP interface devices, and methods of using these devices.

Abstract: Described herein are nasal devices, including nasal devices formed in layers having four or fewer layers. In some variations, the nasal devices include a single integrated layer from which the flap of the airflow resistor is formed as well as the base of the holdfast region. The nasal devices may include a single aligner or rim body on the side of the device facing the subject. The aligner may protect the airflow resistor, and may help center or position the nasal device. In some variations, these nasal devices may include a noise-reduction feature. Also described herein are systems, devices and methods for determining if a passive nasal respiratory device having an airflow resistor configured to inhibit exhalation more than inhalation has been worn by a subject, and thereby confirming compliance.

Abstract: An implantable cardiac device detects a patient therapy request originating from external to the implantable device. A shock therapy delay period is timed in response to the detection of the patient therapy request. Atrial shock therapy is provided to the patient after expiration of the shock therapy delay period (if the presence of an ongoing atrial arrhythmia is detected). The patient therapy request may be provided by a patient activator including a magnet for operating a reed switch in the implanted device to provide the request. A patient activator including an input and receiver/transmitter circuitry may be employed to request the immediate providing of atrial shock therapy, and/or to set the duration the shock therapy delay period. By allowing specific delays to therapy after a therapy request, a patient can prepare for the requested therapy and thereby mitigate therapy discomfort.

Abstract: Described herein are layered nasal devices including layered nasal devices having one or more stiffening members supporting the holdfast region of the nasal device. The stiffening member may be a stress-distributing member or a separate stress-distributing element or member may be included. In some variations the layered nasal device includes a stress distributing element to help prevent wrinkling, de-laminating, buckling, or otherwise disrupting the shape and/or activity of the nasal device. Also described herein are delayed resistance adapters that may be used with a nasal devices that inhibit exhalation more than inhalation (including, but not limited to the adhesive nasal devices described herein). A delayed resistance adapter may be activated to suspend or bypass the increased expiratory resistance of the nasal device. Suspending the increased expiratory resistance may allow the user to allow a user to acclimate to the use of the nasal device.

Abstract: An implantable cardiac device detects a patient therapy request originating from external to the implantable device. A shock therapy delay period is timed in response to the detection of the patient therapy request. Atrial shock therapy is provided to the patient after expiration of the shock therapy delay period (if the presence of an ongoing atrial arrhythmia is detected). The patient therapy request may be provided by a patient activator including a magnet for operating a reed switch in the implanted device to provide the request. A patient activator including an input and receiver/transmitter circuitry may be employed to request the immediate providing of atrial shock therapy, and/or to set the duration the shock therapy delay period. By allowing specific delays to therapy after a therapy request, a patient can prepare for the requested therapy and thereby mitigate therapy discomfort.

Abstract: An implantable cardiac device detects a patient therapy request originating from external to the implantable device. A shock therapy delay period is timed in response to the detection of the patient therapy request. Atrial shock therapy is provided to the patient after expiration of the shock therapy delay period (if the presence of an ongoing atrial arrhythmia is detected). The patient therapy request may be provided by a patient activator including a magnet for operating a reed switch in the implanted device to provide the request. A patient activator including an input and receiver/transmitter circuitry may be employed to request the immediate providing of atrial shock therapy, and/or to set the duration the shock therapy delay period. By allowing specific delays to therapy after a therapy request, a patient can prepare for the requested therapy and thereby mitigate therapy discomfort.

Abstract: Described herein are adjustable-resistance respiratory devices, and particularly nasal devices that have an adjustable expiratory resistance while providing a greater resistance to exhalation than to inhalation. The resistance to exhalation may be manually adjustable by a user or remotely adjustable by a third party. For example, described herein are nasal devices having a greater resistance to exhalation than inhalation that includes one or more resistance-modifying members for modifying the resistance of a nasal device. A resistance modifying member may include a cover, a shutter or an adjustable valve for opening/closing a leak pathway through the nasal device. An adjustable-resistance nasal respiratory device may include a control or controls for adjusting the resistance to exhalation. Methods of adjusting the resistance of a nasal device, and systems including nasal devices allowing the resistance to be optimized and/or adjusted are also described.

Abstract: Described herein are combined active PAP/passive EPAP interface devices to transmit positive air pressure from a PAP source to the user, but provide passive EPAP when the PAP source is disabled. These interface device may continue to provide benefit to the user even if the PAP source becomes disconnected or otherwise fails. The interface devices described herein include a passive EPAP airflow resistor configured to provide expiratory positive airway pressure (“EPAP”). These interface devices may also include quick connects and/or disconnects for releasably connecting to the source of pressurized breathable gas, a quick release for disconnecting from the source of pressurized breathable gas, and an adhesive user interface region that connects the device the user's face. Also described are adapter for converting a PAP interface devices into combined active PAP/passive EPAP interface devices, and methods of using these devices.

Abstract: An apparatus and method of automatically measuring the lead impedance of a high energy shock lead before delivery of high energy therapy used to treat heart arrhythmia. In one example, an impedance measurement circuit measures the impedance between electrodes in a plurality of pairs of electrodes. The measured lead electrode impedance is compared to a predetermined value to detect if the lead is shorted to another lead. If a high-energy shock electrode is shorted to another lead, a shorted lead indicator is set to a fault state. Based on the state of the shorted lead indicator, a processor prevents or allows the delivery of high energy therapy. By checking for a lead short before delivery of the therapy, all of the energy of the therapy is delivered to the patient rather than being bypassed by a shorted lead connection.

Abstract: An implantable cardiac device detects a patient therapy request originating from external to the implantable device. A shock therapy delay period is timed in response to the detection of the patient therapy request. Atrial shock therapy is provided to the patient after expiration of the shock therapy delay period (if the presence of an ongoing atrial arrhythmia is detected). The patient therapy request may be provided by a patient activator including a magnet for operating a reed switch in the implanted device to provide the request. A patient activator including an input and receiver/transmitter circuitry may be employed to request the immediate providing of atrial shock therapy, and/or to set the duration the shock therapy delay period. By allowing specific delays to therapy after a therapy request, a patient can prepare for the requested therapy and thereby mitigate therapy discomfort.

Abstract: An implantable cardiac device detects a patient therapy request originating from external to the implantable device. A shock therapy delay period is timed in response to the detection of the patient therapy request. Atrial shock therapy is provided to the patient after expiration of the shock therapy delay period (if the presence of an ongoing atrial arrhythmia is detected). The patient therapy request may be provided by a patient activator including a magnet for operating a reed switch in the implanted device to provide the request. A patient activator including an input and receiver/transmitter circuitry may be employed to request the immediate providing of atrial shock therapy, and/or to set the duration the shock therapy delay period. By allowing specific delays to therapy after a therapy request, a patient can prepare for the requested therapy and thereby mitigate therapy discomfort.

Abstract: An apparatus and method of automatically measuring the lead impedance of a high energy shock lead before delivery of high energy therapy used to treat heart arrhythmia. In one example, an impedance measurement circuit measures the impedance between electrodes in a plurality of pairs of electrodes. The measured lead electrode impedance is compared to a predetermined value to detect if the lead is shorted to another lead. If a high-energy shock electrode is shorted to another lead, a shorted lead indicator is set to a fault state. Based on the state of the shorted lead indicator, a processor prevents or allows the delivery of high energy therapy. By checking for a lead short before delivery of the therapy, all of the energy of the therapy is delivered to the patient rather than being bypassed by a shorted lead connection.

Abstract: An implantable cardiac device detects a patient therapy request originating from external to the implantable device. A shock therapy delay period is timed in response to the detection of the patient therapy request. Atrial shock therapy is provided to the patient after expiration of the shock therapy delay period (if the presence of an ongoing atrial arrhythmia is detected). The patient therapy request may be provided by a patient activator including a magnet for operating a reed switch in the implanted device to provide the request. A patient activator including an input and receiver/transmitter circuitry may be employed to request the immediate providing of atrial shock therapy, and/or to set the duration of the shock therapy delay period. By allowing specific delays to therapy after a therapy request, a patient can prepare for the requested therapy and thereby mitigate therapy discomfort.

Abstract: An implantable cardiac device detects a patient therapy request originating from external to the implantable device. A shock therapy delay period is timed in response to the detection of the patient therapy request. Atrial shock therapy is provided to the patient after expiration of the shock therapy delay period (if the presence of an ongoing atrial arrhythmia is detected). The patient therapy request may be provided by a patient activator including a magnet for operating a reed switch in the implanted device to provide the request. A patient activator including an input and receiver/transmitter circuitry may be employed to request the immediate providing of atrial shock therapy, and/or to set the duration of the shock therapy delay period. By allowing specific delays to therapy after a therapy request, a patient can prepare for the requested therapy and thereby mitigate therapy discomfort.